Genetic basis of pancreas cancer development and progression: insights from whole-exome and whole-genome sequencing
- PMID: 22896692
- PMCID: PMC3422771
- DOI: 10.1158/1078-0432.CCR-12-0315
Genetic basis of pancreas cancer development and progression: insights from whole-exome and whole-genome sequencing
Abstract
Pancreatic cancer is caused by inherited and acquired mutations in specific cancer-associated genes. The discovery of the most common genetic alterations in pancreatic cancer has provided insight into the fundamental pathways that drive the progression from a normal cell to noninvasive precursor lesions and finally to widely metastatic disease. In addition, recent genetic discoveries have created new opportunities to develop gene-based approaches for early detection, personalized treatment, and molecular classification of pancreatic neoplasms.
Conflict of interest statement
Statement of Conflict of Interest: Under a licensing agreement between Johns Hopkins University and Myriad Genetics, Ralph Hruban and Victor E. Velculescu are entitled to a share of royalty payments received by the University on sales of products related to the PALB2 gene. Victor E. Velculescu is a founder of Personal Genome Diagnostics and Inostics, is member of their Scientific Advisory Boards, and owns Personal Genome Diagnostics and Inostics stock, which is subject to certain restrictions under university policy. The terms of these arrangements are managed by Johns Hopkins University in accordance with its conflict-of-interest policies.
Figures




References
-
- Hruban RH, Pitman MB, Klimstra DS. Atlas of tumor pathology. Washington, DC: American Registry of Pathology and Armed Forces Institute of Pathology; 2007. Tumors of the pancreas.
-
- Shi C, Daniels JA, Hruban RH. Molecular characterization of pancreatic neoplasms. AdvAnatPathol. 2008;15:185–95. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical